From May 9th to 11th, the 2025 World Brand Moganshan Conference with the theme of "Brand, Make the World Better" was held in Deqing, Zhejiang. As one of the important events of the conference, the "2025 Brand High-Quality Overseas Forum" hosted by Xinhuanet and Xinhua News Agency New Media Center was held simultaneously. On the spot, Zhang Yunling, director and deputy general manager of Yiling Pharmaceutical, said in his speech that traditional Chinese medicine is a treasure of Chinese civilization. Yiling Pharmaceutical has always adhered to the corporate purpose of "inheriting innovation and benefiting mankind", promoted the high-quality development of the traditional Chinese medicine industry with full-chain innovation, and shared practical results from three aspects: scientific and technological innovation, industrial chain coordination, and international layout.

Zhang Yunling, Director and Deputy General Manager of Yiling Pharmaceutical, made a speech

Technological innovation creates a high-quality development engine

Zhang Yunling pointed out that inheriting the essence and maintaining integrity and innovation are the key paths for the high-quality development of traditional Chinese medicine. Yiling Pharmaceutical’s academician team systematically constructed a theoretical system for the network disease, and established a national key laboratory for the innovation and transformation of network disease theory, deeply integrated traditional Chinese medicine with modern technology, and developed a total of 17 innovative patented Chinese medicines, winning the National Science and Technology Award six times.

In the field of respiratory diseases, Lianhua Qingwen and Lianhua Qingke Tablets have become representative drugs for the treatment of respiratory infectious diseases. For cardiovascular and cerebrovascular diseases, the national key R&D program "Research on Intervention of Cardiovascular Events Chain" led by Professor Jia Zhenhua of the Hebei Provincial Institute of Luxury Innovation Medicine has been completed, and four sub-topic research has been published in the top international journals.

Among them: Tongxinluo Capsule reduces the risk of death from acute myocardial infarction by 30% and the risk of recurrence by 74%. The study was published in the Journal of the American Medical Association; Jinlida Granules have been confirmed to reduce the risk of diabetes by 41%, and improve glycolipid metabolism, etc.; Shensongyangxin Capsule solves the problem of cardiovascular disease of arrhythmia with heart failure and recurrence of atrial fibrillation after radiofrequency ablation; Qifeng Qiangxin Capsule reduces the risk of death from chronic heart failure by 17% and the risk of re-hospitalization by 24%. The research results are released at the annual meeting of the European Society of Cardiology.

In the field of anti-aging, Bazi Bushen Capsules have comprehensive advantages in anti-aging and preventing and treating aging-related diseases by intervening in the 10 internationally recognized aging mechanisms.

Industrial chain innovation lays the foundation for high-quality development

Zhang Yunling emphasized that Yiling Pharmaceutical has built a five-in-one operating model of "theory-clinical-scientific research-industry-teaching" to form a layout with the traditional Chinese medicine industry as the core and coordinated development in multiple fields. The company has created more than 60 large-scale and standardized Chinese medicinal materials breeding bases in more than 20 provinces across the country, covering more than 40 varieties, becoming an engine for rural revitalization and industrial development.

"The construction of these bases not only allows local farmers to achieve continuous income growth, but also allows many barren mountains and wastelands to be covered with green." She said that by extending the industrial chain, the construction of bases has achieved an organic combination of industrial innovation and ecological benefits, which not only provides farmers with the "golden key" to get rich, but also lays a solid industrial foundation for high-quality development.

Yiling Pharmaceutical is also promoting the deep integration of traditional Chinese medicine and AI digital technology. Zhang Yunling said that at present, the company has begun to use locally deployed AI models to empower innovative traditional Chinese medicine research and development and production.

Open innovation promotes traditional Chinese medicine to the world

Zhang Yunling said that Yiling Pharmaceutical has promoted the process of "going out" traditional Chinese medicine by strengthening international exchanges and cooperation. The company has promoted the establishment of more than 100 professional committees for cyber disease at home and abroad, and has carried out cooperative research with many international medical research institutions to accelerate international product registration. At present, innovative Chinese medicines such as Lianhua Qingwen, Tongxinluo, and Bazi kidney tonic have entered more than 50 countries and regions around the world.

Regarding future development, Zhang Yunling said that Yiling Pharmaceutical will focus on scientific research and transformation of scientific and technological innovation achievements, injecting inexhaustible impetus into the high-quality development of the traditional Chinese medicine industry; at the same time, further strengthen international exchanges and cooperation, promote traditional Chinese medicine products to the world, and contribute to the building of a community of health and health for mankind.

[Editor in charge: Wu Qilong]